e-therapeutics_primary_logo.png
e-therapeutics Announces Business Updates and Interim Results
October 31, 2024 09:00 ET | e-therapeutics plc
LONDON, Oct. 31, 2024 (GLOBE NEWSWIRE) -- e-therapeutics plc, a company integrating computational power and biological data to discover life-transforming RNAi medicines, today announced business...
Gyre Logo.png
Gyre Therapeutics Announces Last Patient Completed Pivotal Phase 3 Trial Evaluating F351 for CHB-Associated Liver Fibrosis
October 22, 2024 16:05 ET | Gyre Therapeutics, Inc.
Gyre Therapeutics Announces Last Patient Completed Pivotal Phase 3 Trial Evaluating F351 for CHB-Associated Liver Fibrosis
Inventiva annonce un
Inventiva annonce un financement allant jusqu’à 348 millions d'euros afin d’avancer l’étude NATiV3 de Phase 3 dans la MASH
October 14, 2024 02:30 ET | INVENTIVA
► Inventiva obtient 94,1 millions d’euros dans le cadre d’un financement en plusieurs tranches d'un montant maximum de 348 millions d'euros, sous réserve de la réalisation de certaines conditions,...
Inventiva announces
Inventiva announces financing of up to €348 million to advance the NATiV3 Phase 3 MASH study
October 14, 2024 02:30 ET | INVENTIVA
Inventiva secures €94.1 million of a multi-tranche equity financing of up to €348 million, subject to satisfaction of specified conditions, from both new and existing investors, and up to $30 million...
111Boehringer_Ingelheim_Logo_RGB_Dark_Green (002).png
Boehringer receives U.S. FDA Breakthrough Therapy designation and initiates two phase III trials in MASH for survodutide
October 08, 2024 02:35 ET | Boehringer Ingelheim
The U.S. FDA Breakthrough Therapy designation is for the treatment of adults with non-cirrhotic metabolic dysfunction-associated steatohepatitis (MASH) and moderate or advanced fibrosis, based on...
Gyre Logo.png
Gyre Therapeutics to Present at 8th Annual H.C. Wainwright MASH Investor Conference
October 01, 2024 16:05 ET | Gyre Therapeutics, Inc.
Gyre Therapeutics to Present at 8th Annual H.C. Wainwright MASH Investor Conference
Gyre Logo.png
Gyre Therapeutics to Present at Sidoti Virtual Investor Conference
August 09, 2024 07:00 ET | Gyre Therapeutics, Inc.
Gyre Therapeutics to Present at Sidoti Virtual Investor Conference
Gyre Logo.png
Gyre Therapeutics Announces Appointment of David M. Epstein, Ph.D., to Board of Directors
August 08, 2024 16:05 ET | Gyre Therapeutics, Inc.
Gyre Therapeutics Announces Appointment of David M. Epstein, Ph.D., to Board of Directors
canfite_logo.jpg
Join Can-Fite’s Exclusive Live Investor Webinar and Q&A Session on August 8
July 17, 2024 07:00 ET | Can-Fite BioPharma Ltd.
RAMAT GAN, Israel, July 17, 2024 (GLOBE NEWSWIRE) --  Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE: CFBI), a biotechnology company advancing a pipeline of proprietary small molecule drugs...
111Boehringer_Ingelheim_Logo_RGB_Dark_Green (002).png
Boehringer Ingelheim’s survodutide shows breakthrough improvement in liver fibrosis with no worsening of MASH in 64.5% of patients with F2 and F3 fibrosis
June 07, 2024 04:30 ET | Boehringer Ingelheim
News builds on previously announced primary endpoint, which showed up to 83.0% of adults achieved statistically significant improvement in metabolic dysfunction-associated steatohepatitis (MASH)...